Jaguar Health Registers 41M Shares for Resale Under $40M Equity Line — Potential 89% Dilution

summarizeSummary

Jaguar Health registered 41 million shares for resale under its $40M equity line, creating potential dilution of over 89% if fully utilized. The filing confirms deeply discounted purchase mechanics and $800K in commitment shares payable to the investor.

check_boxKey Events · Financing and Capital Events · JAGX

• 41M Share Resale Registration

  The S-1 registers resale of up to 41,000,000 shares under the $40M equity line with C/M Capital — if all issued, they would represent over 89.3% of the 4.9M shares currently outstanding.

• Deeply Discounted Purchase Mechanics

  VWAP purchases are priced at 95% of the lowest of the VWAP, the 5-day low, or the closing price — guaranteeing the investor always buys at a discount to market, creating immediate resale incentive.

• $800K Commitment Shares Due

  Upon registration effectiveness, the company must issue $800,000 worth of common stock to the investor as Commitment Shares — additional dilution with no cash proceeds to Jaguar.

• Series P Preferred Stock Financing

  A concurrent $2M private placement of Series P Preferred Stock includes pre-funded warrants for $72,000 in shares, adding further potential dilution.

auto_awesomeAnalysis · JAGX · Life Sciences

An S-1 filed by Jaguar Health registers the resale of up to 41 million shares under its $40 million equity line with C/M Capital. If fully drawn and sold, these shares would represent over 89% of the current outstanding, creating a massively dilutive overhang. The filing reveals that the investor always buys at a discount — VWAP purchases are priced at 95% of the lowest recent price — and the company must issue $800,000 in Commitment Shares just to activate the facility. Against a backdrop of recent Nasdaq compliance struggles and a $5M market cap, this registration makes the dilution threat concrete and tradable, giving the investor a clear path to sell into any strength.